Recombinant factor VIIa in a patient with Glanzmann’s thrombasthenia undergoing gynecological surgery: open issues in light of successful treatment

Antonio Coppola; Antonella Tufano; Ernesto Cimino; Annalisa Agangi; Giuseppe Maria Maruotti; Pasquale Martinelli; Giovanni Di Minno

doi:10.1055/s-0037-1614304

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2004; 92(06): 1450-1452
DOI: 10.1055/s-0037-1614304

Letters to the Editor

Schattauer GmbH

Recombinant factor VIIa in a patient with Glanzmann’s thrombasthenia undergoing gynecological surgery: open issues in light of successful treatment

Authors

Antonio Coppola

²Centro di Coordinamento Regionale per le Emocoagulo-patie, Department of Clinical and Experimental Medicine
Antonella Tufano

²Centro di Coordinamento Regionale per le Emocoagulo-patie, Department of Clinical and Experimental Medicine
Ernesto Cimino

²Centro di Coordinamento Regionale per le Emocoagulo-patie, Department of Clinical and Experimental Medicine
Annalisa Agangi

¹Department of Gynecological and Obstetric Emergencies, “Federico II” University, Naples, Italy
Giuseppe Maria Maruotti

¹Department of Gynecological and Obstetric Emergencies, “Federico II” University, Naples, Italy
Pasquale Martinelli

¹Department of Gynecological and Obstetric Emergencies, “Federico II” University, Naples, Italy
Giovanni Di Minno

²Centro di Coordinamento Regionale per le Emocoagulo-patie, Department of Clinical and Experimental Medicine

Abstract

Volltext

Referenzen

References
1 Tengborn L, Peturson B. A patient wth Glanzmann’s thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996; 75: 981-2.
2 Poon M-C, d’Oiron R. Recombinant activated factor VII (NovoSeven®) treatment of platelet-related bleeding disorders. Blood Coagul Fibrinolysis 2000; 1 (Suppl. 01) 55-68.
3 Poon M-C, d’Oiron R, Von Depka M. et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann’s thrombasthenia: results of an international survey. J Thromb Haemost 2004; 02: 1096-103.
4 D’Andrea G, Colaizzo D, Vecchione G. et al. on behalf of the GLAnzmann’s Thrombasthenia Italian Team (GLATIT). Glanzmann’s Thrombasthenia: identification of 19 new mutations in 30 patients. Thromb Haemost 2002; 87: 1034-42.
5 Monroe DM, Hoffman M, Allen GA. et al. The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost 2000; 26: 373-7.
6 d’Oiron R, Menart C, Trzeciak MC. et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann’s thrombasthenia undergoing invasive procedures. Thromb Haemost 2000; 83: 644-7.
7 Abshire CT Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: improved efficacy with higher dosing. Semin Hematol 2004; 41 (Suppl. 01) 3-7.
8 Santagostino E, Morfini M, Rocino A. et al. Relationship between Factor VII activity and clinical efficacy of recombinant factor VIIa given by continous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001; 86: 954-8.
9 Kawaguchi C, Takahashi Y, Hanesaka Y. et al. The in vitro analysis of the coagulation mechanism of activated factor VII using thrombe-lastogram. Thromb Haemost 2002; 88: 768-72.
10 Gabriel DA, Carr M, Roberts HR. Monitoring coagulation and the clinical effects of recombinant Factor VIIa. Semin Hematol 2004; 41 (Suppl. 01) 20-4.
11 Robinson KL, Savoia H, Street AM. Thrombotic complications in two patients receiving NovoSeven®. Haemophilia 2000; 06: 349.
12 Wielenga JJ, Siebel Y, van Buuren HR. et al. Use of recombinant factor VIIa and HLA matched platelets to prevent bleeding during and after major surgery in a patient with Glanzmann’s thrombasthenia. Haemophilia 1998; 04: 299.